Skip to main content
Premium Trial:

Request an Annual Quote

Deborah Keller

Laboratory Corporation of America has named Deborah Keller as the CEO of Covance Drug Development. She takes over for Joseph Herring who will retire on July 31 after more than a decade as CEO.

Keller joined Covance in 1987 and has held senior leadership roles in global operations, quality assurance, and marketing. Most recently she served as executive vice president of Covance and group president of R&D Laboratories where she led more than 6,000 employees at 18 facilities across the globe. 

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.